knowledge -WSS

knowledge

author：focus 2025-08-12 11:29:01 - browse：738

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

WSS

Why Congress must ban federal programs from using QALYs

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Vir antibody drug aimed at influenza A fails in clinical trial

Pfizer highlights cancer drugs it thinks could reignite investor interest

Stanford president faces new allegations over 1999 paper

A Q&A with Aletha Maybank, AMA’s chief health equity officer

knowledge

knowledge

focus

Drug repurposing or repositioning? The language matters

FogPharma raises $145 million in rare Series E round

Alkermes shareholders re

Covid isolation guidance eased by the CDC

Medicare details structure of new drug price negotiation program

An inside look at PIPEs, biotech's buzzy new financing tool

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Clinical trials giant ICON acquires HumanFirst

Cancer drug shortages should be causing more outrage

Stanford president faces new allegations over 1999 paper

explore

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

7 more heat

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Indian pharmaceutical industry in denial over drug

Vir antibody drug aimed at influenza A fails in clinical trial

Covid isolation guidance eased by the CDC

hotspot

entertainment

leisure time

focus